REPORT SCOPE
INTRODUCTION
STUDY GOALS AND OBJECTIVES
The objective of this study is to review the status of next generation cancer diagnostic technologies and assays, and assess their worldwide growth potential over a 5-year period from 2010 to 2015. We are particularly interested in characterizing the markets for the key next generation platforms: real time polymerase chain reaction (RT-PCR), DNA microarrays, lab-on-a-chip (LOAC), protein microarrays, circulating tumor cells (CTCs), and multiplexed conventional and next generation sequencing.
A main focus of this report is genomic, epigenomic, proteomic, and cellular analysis in which the majority of cancer diagnostics sales occur.
Our main objective is to present a comprehensive review of next generation platforms by cancer indication to assess the future market potential of the industry.
REASONS FOR DOING THE STUDY
Cancer is a collection of diseases caused by genetic malfunctions. The recent explosion in genomic and proteomic information since the completion of the Human Genome Project has created enormous diagnostic content that has been correlated with cancer progression. During this same time period, there has been tremendous scientific progress in novel analysis technologies, including lab-on-a-chip, RT-PCR, high-density microarrays, next generation sequencing, cellular capture and identification, and multiplexed assays.
These technological forces are merging with unmet medical diagnostic needs to create favorable conditions for future commercial growth. Thus, it is particularly timely to review the market opportunities and future growth of specific cancer diagnostic market segments.
The next generation cancer diagnostics industry is currently a small but growing segment of the in vitro diagnostics industry. Some tests are already established, for example in cervical cancer screening or breast cancer prognostics. A significant number of new assays using innovative platforms are in the diagnostic pipeline. For companies seeking to exploit the growth in this industry, it is important to understand the various next generation platforms and their development status for each cancer indication.
Given the emerging nature of this industry, it is timely to analyze the key trends, markets, and industry dynamics to provide a useful basis for corporate decision making.
INTENDED AUDIENCE
We have compiled a study of the main next generation platforms that will be important in key end user segments. We analyze the diagnostics market by cancer indication (e.g., breast, colorectal, prostate, etc.), by type of analysis (e.g., gene expression, genotyping, proteomic, etc.), and by diagnostic function (e.g., screening/early detection, prognosis, monitoring/recurrence, and companion diagnostic).
We examine the next generation diagnostic technologies, forces driving industry growth, product types, key market applications, companies, corporate alliances, future market potential, and product sales forecasts for the period 2010 through 2015.
We analyze industry dynamics, including each of the distinct industry subsegments as well as recent corporate acquisitions and alliances.
This study will be of particular interest to companies in the following industries: in vitro diagnostics, pharmaceuticals, biotechnology, nanomaterials, life sciences tools and reagents, medical devices, DNA sequencing, DNA microarrays, protein microarrys, biochips, lab-on-a-chip, PCR, clinical laboratories, and bioinformatics.
SCOPE OF REPORT
The study scope includes the major next generation formats that are likely to become commercialized within the next 5 years. Each technology format is analyzed to determine its market status, impact on future market segments, and projected growth from 2010 through 2015. Technology issues and forces driving the market are discussed.
Influencing factors, including cancer diagnostics needs, regulatory trends, industry structure, and patent status are also discussed.
BCC examines companies in the industry, corporate alliances, and assay consumption by indication. We profile 108 companies participating in the industry.
METHODOLOGY
BCC presents an analysis of each of the key market segments that will be commercially important during the next 5 years: RT-PCR, DNA microarrays, protein microarrays, LOAC, CTC, next generation sequencing, and multiplexed conventional.
Based on our analysis, we evaluate the potential applications of next generation platforms in each of the major market segments, and forecast sales revenues for 2010 through 2015.
For each technology platform, we provide a market analysis and forecast from 2010 through 2015 by cancer indication, by analysis type performed, and by diagnostic function. For each analysis type (e.g., detection/early screening), we forecast the market size by cancer indication. For selected key cancer indications, we provide a detailed forecast of the next generation technology formats. Finally, we forecast the overall market by geographical region.
INFORMATION SOURCES
Both primary and secondary information sources were used in preparing this study. BCC surveyed life science companies and research institutions to obtain data for this study. Included were research tools, diagnostics, drug firms, as well as leading research institutions. In addition, we compiled data from secondary sources, including industry, trade, and government organizations.
ANALYST CREDENTIALS
The author, John Bergin, has written previous BCC Research biotechnology reports titled Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics, and Therapeutics; Global Biochip Markets: Microarrays and Lab-on-a-Chip; RNA Interference in the Post-Genomics Era: Markets and Technologies; Synthetic Biology: Emerging Global Markets; Biologic Imaging Reagents: Technologies and Global Markets; DNA Sequencing: Emerging Technologies and Applications; Nanobiotechnology: Applications and Global Markets. Mr. Bergin has held business development, sales, and marketing positions with a Fortune 500 advanced materials company as well as executive management positions with a separations company. Mr. Bergin holds the following degrees: B.S. in Chemistry, M.S. in Biotechnology, and an M.B.A.
BCC ONLINE SERVICES
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
- Examine BCC’s complete catalog of Market Research Reports and place direct orders
- Subscribe to any of BCC’s many industry newsletters
- Read announcements of recently published reports and newly launched newsletters
- Register for BCC’s well-known conferences
- Request additional information on any BCC product
- Take advantage of special offers.
DISCLAIMER
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or from its use.
